- Trials with a EudraCT protocol (7,393)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7,393 result(s) found for: Disease Control.
Displaying page 1 of 370.
EudraCT Number: 2021-006055-33 | Sponsor Protocol Number: HypoGI | Start Date*: 2023-03-05 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Assessing the feasibility of pharmacologically induced hypothyroidism in patients with advanced pancreatic cancer - a pilot study | ||
Medical condition: Patients with newly diagnosed metastatic pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001059-37 | Sponsor Protocol Number: AKST4290-221 | Start Date*: 2019-06-21 | |||||||||||
Sponsor Name:Alkahest, Inc. | |||||||||||||
Full Title: Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | |||||||||||||
Medical condition: Mild to Moderate Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004523-21 | Sponsor Protocol Number: V1605-201 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:DBV Technologies S.A. | |||||||||||||
Full Title: A Phase 2 Study to Evaluate the Sensitivity and Specificity of DBV1605, a Ready to Use Atopy Patch Test for the Diagnosis of Non-Immunoglobulin E Mediated Cow’s Milk Allergy in Children. | |||||||||||||
Medical condition: Non-Immunoglobulin E Mediated Cow’s Milk Allergy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005966-35 | Sponsor Protocol Number: KKS/INNERE_A/AML2006 | Start Date*: 2006-07-24 |
Sponsor Name:Universitätsklinikum Münster | ||
Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML | ||
Medical condition: Patients older than 60 years with newly diagnosed acute myeloid leukemia (AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004373-40 | Sponsor Protocol Number: AveNEC | Start Date*: 2017-08-21 |
Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz | ||
Full Title: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) pr... | ||
Medical condition: advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005523-15 | Sponsor Protocol Number: ulcn0107 | Start Date*: 2008-07-17 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small ce... | ||
Medical condition: advanced non-small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001440-26 | Sponsor Protocol Number: PrevenCOVID-19 | Start Date*: 2020-04-19 |
Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | ||
Full Title: Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare pe... | ||
Medical condition: Prevention of SARS-CoV-2 (COVID-19) infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001724-19 | Sponsor Protocol Number: 2013/2 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
Full Title: Pilot study to assess P-glycoprotein function at the blood-brain barrier of patients with mild to moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer's disease and healthy controls (2 groups: 1 group with young healthy volunteers, 1 group with elderly healthy volunteers) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001854-23 | Sponsor Protocol Number: AMMURAVID | Start Date*: 2020-04-27 |
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | ||
Full Title: Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004462-18 | Sponsor Protocol Number: CRCFL12 | Start Date*: 2013-04-23 |
Sponsor Name:Service of Neurology CHU Liege | ||
Full Title: An exploratory research on the influence of amyloid deposit (measured with (18F)flutemetamol) on disconnection in the “core episodic network” and between regions involved in anosognosia for memory ... | ||
Medical condition: Alzheimer's disease (mild, moderate and moderately severe stage) and control population | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000301-71 | Sponsor Protocol Number: TJB1117P1 | Start Date*: 2013-01-25 | |||||||||||
Sponsor Name:CHU-ULg | |||||||||||||
Full Title: Donor Regulatory T cells (Treg) infusion (DTI) in patients with steroid-refractory chronic graft-versus-host disease (GVHD). | |||||||||||||
Medical condition: Steroid-refractory chronic graft-versus-host-disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005745-20 | Sponsor Protocol Number: IPR/26 | Start Date*: 2013-03-24 |
Sponsor Name:MolMed S.p.A. | ||
Full Title: NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer | ||
Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014799-23 | Sponsor Protocol Number: PH-L19IL2-03/09 | Start Date*: 2010-02-04 | ||||||||||||||||
Sponsor Name:Philogen S.p.A | ||||||||||||||||||
Full Title: A phase II study of intratumoral application of L19IL2 in patients with stage III/IV melanoma | ||||||||||||||||||
Medical condition: Cancer- Patients with histopathologically-proven malignant melanoma with presence of measurable and injectable dermal or subcutaneous metastases either in clinical stage III or stage IV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001442-15 | Sponsor Protocol Number: CFTY720D2324 | Start Date*: 2011-08-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from... | |||||||||||||
Medical condition: relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) ES (Completed) GR (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) HU (Completed) SE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001954-28 | Sponsor Protocol Number: CQAB149B2334 | Start Date*: 2006-10-10 | |||||||||||
Sponsor Name:NovartisPharma Services AG | |||||||||||||
Full Title: A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.)... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DK (Completed) HU (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) EE (Completed) LT (Completed) SE (Completed) LV (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003830-26 | Sponsor Protocol Number: LPRI-421/201 | Start Date*: 2017-02-24 | |||||||||||
Sponsor Name:Exeltis France | |||||||||||||
Full Title: Single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of Dienogest and Ethinyl Estra... | |||||||||||||
Medical condition: Women’s healthcare (contraception, inhibition of ovulation). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006793-28 | Sponsor Protocol Number: CL3-16257-078 | Start Date*: 2008-09-18 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | |||||||||||||
Full Title: Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary arte... | |||||||||||||
Medical condition: Heart rate control during a MultiSlice Computed Tomography Coronary Angiography (MST CA) for the evaluation of Coronary Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) BE (Completed) PT (Completed) HU (Completed) ES (Completed) DE (Completed) FR (Completed) DK (Completed) IT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001540-22 | Sponsor Protocol Number: MD2019 | Start Date*: 2020-01-22 |
Sponsor Name:Abteilung für Hals- Nasen- Ohrenkrankheiten MUW, AKH Wien | ||
Full Title: Assessment of vertigo control rate following common treatments in Menière´s disease | ||
Medical condition: In our study we try to evaluate the the effect of common therapies in Menière´s disease patients on vertigo control calculation, Hydrops MRI, vHIT (video head impuls test) , caloric testing, audiol... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003859-61 | Sponsor Protocol Number: PM0259CA232J1 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy | |||||||||||||
Medical condition: Advanced Non Small Lung Cancer unfit for a platinium-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PL (Completed) HU (Completed) CZ (Completed) DE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004287-23 | Sponsor Protocol Number: P04592 | Start Date*: 2006-12-05 | |||||||||||
Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation | |||||||||||||
Full Title: Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.